Mursla Bio has announced a collaboration with a leading global pharmaceutical company to advance biomarker-guided precision medicine in metabolic dysfunction-associated steatohepatitis (MASH). The partnership will leverage Mursla Bio’s AI Precision Medicine Platform to generate hepatocyte-specific extracellular vesicle (h-EV) profiles from blood samples of patients with MASH and matched healthy controls.

The collaboration aims to identify mode-of-action (MoA) biomarkers and evaluate biomarker panels that can stratify patients most likely to benefit from the pharmaceutical company’s investigational therapy. In its initial phase, the partnership will focus on building tissue-labeled, high-dimensional mRNA and protein datasets from h-EVs in blood, providing insights into liver tissue biology and supporting the development of predictive patient stratification signatures.

Pierre Arsène, founder and CEO of Mursla Bio, said: “This collaboration reflects the growing demand from global pharmaceutical leaders for our AI Precision Medicine Platform. As the GLP-1 revolution reshapes obesity management, MASH is rapidly emerging as the next major therapeutic focus, and the need for precise liver-specific biomarkers has never been greater. By profiling intact hepatocyte biology protected within the cargo of h-EVs, we are enabling a new generation of biomarker-guided precision medicine in liver care.”

Mursla Bio will build on its clinically validated platform established with EvoLiver™, developed for liver cancer surveillance in cirrhotic patients, which previously achieved FDA Breakthrough Device Designation. The platform will accelerate the translation of exploratory biomarkers into regulatory-grade companion diagnostics, extending its applicability across metabolic liver diseases.

MASH is an advanced form of fatty liver disease, strongly associated with obesity and type 2 diabetes. It affects 5–7% of the global adult population, with more than 75% of affected individuals classified as overweight, obese, or living with type 2 diabetes. The condition is characterized by the accumulation of excess fat in the liver, leading to inflammation and cell damage. If untreated, MASH can progress to cirrhosis, liver failure, or liver cancer.

Through this partnership, Mursla Bio and its pharmaceutical collaborator aim to accelerate precision medicine approaches in hepatology, supporting drug development and patient stratification strategies that target the underlying biology of MASH and potentially improve outcomes for patients at risk of advanced liver disease.